Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936704 | 0.81 | TSHR (0.43) | TSHRDGKASMN1; SMN2HCAR2ADRA2A | |
| SCHEMBL10011308 | 0.80 | HCAR2 (0.42) | TSHRDGKAHCAR2ALDH1A1 | |
| SCHEMBL12050130 | 0.79 | TSHR (0.42) | TSHRDGKASMN1; SMN2HCAR2ADRA2A | |
| SCHEMBL10011568 | 0.79 | ALDH1A1 (0.52) | TSHRDGKASMN1; SMN2ALDH1A1 | |
| SCHEMBL9275566 | 0.77 | TSHR (0.41) | TSHRDGKASMN1; SMN2ADRA2AADRA1A | |
| SCHEMBL10011059 | 0.77 | ATM (0.52) | TSHRDGKAHCAR2ALDH1A1 | |
| SCHEMBL20862160 | 0.76 | TSHR (0.39) | TSHRDGKASMN1; SMN2ADRA2AADRA1A | |
| SCHEMBL15108347 | 0.76 | TSHR (0.39) | TSHRDGKASMN1; SMN2HCAR2ADRA2A | |
| SCHEMBL13313904 | 0.76 | TSHR (0.39) | TSHRDGKASMN1; SMN2ADRA2AADRA1A | |
| SCHEMBL16285424 | 0.76 | ALDH1A1 (0.41) | TSHRDGKASMN1; SMN2ADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9130244-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| EP-2908376-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2479831-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | SLC8A1, OR10J3, SLC8B1 | TSHR 3669/4885DGKA 1127/4885SMN1; SMN2 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.